Literature DB >> 35080425

Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4+ T Cell.

Jérémie Prévost1,2, Jonathan Richard1,2, Romain Gasser1,2, Halima Medjahed1, Frank Kirchhoff3, Beatrice H Hahn4,5, John C Kappes6, Christina Ochsenbauer6, Ralf Duerr7, Andrés Finzi1,2,8.   

Abstract

The HIV-1 Nef and Vpu accessory proteins are known to protect infected cells from antibody-dependent cellular cytotoxicity (ADCC) responses by limiting exposure of CD4-induced (CD4i) envelope (Env) epitopes at the cell surface. Although both proteins target the host receptor CD4 for degradation, the extent of their functional redundancy is unknown. Here, we developed an intracellular staining technique that permits the intracellular detection of both Nef and Vpu in primary CD4+ T cells by flow cytometry. Using this method, we show that the combined expression of Nef and Vpu predicts the susceptibility of HIV-1-infected primary CD4+ T cells to ADCC by HIV+ plasma. We also show that Vpu cannot compensate for the absence of Nef, thus providing an explanation for why some infectious molecular clones that carry a LucR reporter gene upstream of Nef render infected cells more susceptible to ADCC responses. Our method thus represents a new tool to dissect the biological activity of Nef and Vpu in the context of other host and viral proteins within single infected CD4+ T cells. IMPORTANCE HIV-1 Nef and Vpu exert several biological functions that are important for viral immune evasion, release, and replication. Here, we developed a new method allowing simultaneous detection of these accessory proteins in their native form together with some of their cellular substrates. This allowed us to show that Vpu cannot compensate for the lack of a functional Nef, which has implications for studies that use Nef-defective viruses to study ADCC responses.

Entities:  

Keywords:  ADCC; BST-2; CD4; CD4-bound conformation; Env; HIV-1; LucR.T2A; Nef; Vpu; nonneutralizing antibodies

Mesh:

Substances:

Year:  2022        PMID: 35080425      PMCID: PMC8941894          DOI: 10.1128/jvi.01929-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  159 in total

Review 1.  Impact of HIV-1 Envelope Conformation on ADCC Responses.

Authors:  Jonathan Richard; Jérémie Prévost; Nirmin Alsahafi; Shilei Ding; Andrés Finzi
Journal:  Trends Microbiol       Date:  2017-11-20       Impact factor: 17.079

2.  Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor.

Authors:  Rittik Chaudhuri; O Wolf Lindwasser; William J Smith; James H Hurley; Juan S Bonifacino
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

3.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Authors:  Nanette Van Damme; Daniel Goff; Chris Katsura; Rebecca L Jorgenson; Richard Mitchell; Marc C Johnson; Edward B Stephens; John Guatelli
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

4.  HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells.

Authors:  Hugues Fausther-Bovendo; Nathalie Sol-Foulon; Daniel Candotti; Henri Agut; Olivier Schwartz; Patrice Debré; Vincent Vieillard
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

5.  HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells.

Authors:  Metka Lenassi; Gerard Cagney; Maofu Liao; Tomaz Vaupotic; Koen Bartholomeeusen; Yifan Cheng; Nevan J Krogan; Ana Plemenitas; B Matija Peterlin
Journal:  Traffic       Date:  2010-01       Impact factor: 6.215

6.  Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein.

Authors:  O Schwartz; V Maréchal; S Le Gall; F Lemonnier; J M Heard
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

7.  Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.

Authors:  Julie L Mitchell; Justin Pollara; Kenneth Dietze; R Whitney Edwards; Junsuke Nohara; Kombo F N'guessan; Michelle Zemil; Supranee Buranapraditkun; Hiroshi Takata; Yifan Li; Roshell Muir; Eugene Kroon; Suteeraporn Pinyakorn; Shalini Jha; Sopark Manasnayakorn; Suthat Chottanapund; Pattarawat Thantiworasit; Peeriya Prueksakaew; Nisakorn Ratnaratorn; Bessara Nuntapinit; Lawrence Fox; Sodsai Tovanabutra; Dominic Paquin-Proulx; Lindsay Wieczorek; Victoria R Polonis; Frank Maldarelli; Elias K Haddad; Praphan Phanuphak; Carlo P Sacdalan; Morgane Rolland; Nittaya Phanuphak; Jintanat Ananworanich; Sandhya Vasan; Guido Ferrari; Lydie Trautmann
Journal:  J Clin Invest       Date:  2022-01-04       Impact factor: 14.808

8.  Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors.

Authors:  Tonya Kueck; Toshana L Foster; Julia Weinelt; Jonathan C Sumner; Suzanne Pickering; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2015-08-28       Impact factor: 6.823

9.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha.

Authors:  Angharad E Fenton-May; Oliver Dibben; Tanja Emmerich; Haitao Ding; Katja Pfafferott; Marlen M Aasa-Chapman; Pierre Pellegrino; Ian Williams; Myron S Cohen; Feng Gao; George M Shaw; Beatrice H Hahn; Christina Ochsenbauer; John C Kappes; Persephone Borrow
Journal:  Retrovirology       Date:  2013-12-03       Impact factor: 4.602

10.  HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4+ T Cells.

Authors:  Jérémie Prévost; Cassandra R Edgar; Jonathan Richard; Steven M Trothen; Rajesh Abraham Jacob; Mitchell J Mumby; Suzanne Pickering; Mathieu Dubé; Daniel E Kaufmann; Frank Kirchhoff; Stuart J D Neil; Andrés Finzi; Jimmy D Dikeakos
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

View more
  3 in total

1.  Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.

Authors:  Saumya Anang; Jonathan Richard; Catherine Bourassa; Guillaume Goyette; Ta-Jung Chiu; Hung-Ching Chen; Amos B Smith; Navid Madani; Andrés Finzi; Joseph Sodroski
Journal:  J Virol       Date:  2022-08-18       Impact factor: 6.549

2.  Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.

Authors:  Marianne Boutin; Dani Vézina; Shilei Ding; Jérémie Prévost; Annemarie Laumaea; Lorie Marchitto; Sai Priya Anand; Halima Medjahed; Gabrielle Gendron-Lepage; Catherine Bourassa; Guillaume Goyette; Andrew Clark; Jonathan Richard; Andrés Finzi
Journal:  mBio       Date:  2022-04-27       Impact factor: 7.786

3.  Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission.

Authors:  Allison S Thomas; Carolyn Coote; Yvetane Moreau; John E Isaac; Alexander C Ewing; Athena P Kourtis; Manish Sagar
Journal:  JCI Insight       Date:  2022-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.